EGFR and non-small cell squamous lung carcinoma: While the indication for necitumumab is for patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) expressing squamous non-small cell lung cancer, a direct reference to the use of a validated test was missing in the SmPC section 4.2/4.4; whereas reference to a CE-marked test was included in section 5.1.